Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

Julian Alexander Portocarrero Nuñez, MD,a,∗ Juan Gonzalez-Garcia, MD,b Juan Berenguer, MD,c María Jesús Vivancos Gallego, MD,d Jose Antonio Iribarren Loyarte, MD,e Luis Metola, MD,f Enrique Bernal, MD,g Gemma Navarro, MD,h Julia Del Amo, MD, PhD,i Inmaculada Jarrín, PhD,i and the Cohort of the Spanish HIV Research Network (CoRIS)

Abstract
We assessed the effect of co-infection by hepatitis C virus (HCV) on immunological and virological response at 48 weeks from initiation of antiretroviral therapy (ART).

We included patients from the Cohort of Spanish HIV Research Network (CoRIS) starting ART between January 2004 and November 2014, had at least 1 CD4 T-cell count and viral load measurements both in the previous 6 months and at 48 (±12) weeks from ART initiation, and HCV serology before ART initiation. We used linear regression for mean differences in CD4 T-cell count increase from ART initiation and logistic regression to estimate odds ratios for virological response.

Of 12,239 patients by November 30, 2015, 5070 met inclusion criteria: 4382 (86.4%) HIV mono-infected and 688 (13.6%) HIV/HCV co-infected. Co-infected patients were more likely to have acquired HIV through injecting drugs use (57.4% vs. 1.1%), to be women, older, and Spanish, have a lower educational level, and have started ART with lower CD4 counts and acquired immunodeficiency syndrome. CD4 T-cell count increase at 48 weeks was 229.7 cell/μL in HIV-monoinfected and 161.9 cell/μL in HIV/HCV-coinfected patients. The percentages of patients achieving a virological response at 48 weeks were 87.0% and 78.3% in mono and coinfected patients, respectively. Multivariable analyses showed that at 48 weeks, coinfected patients increased 44.5 (95% confidence interval [CI]: 24.8–64.3) cells/μL less than monoinfected and had lower probability of virological response (odds ratio: 0.62; 95% CI: 0.44–0.88).

HIV/HCV-coinfected patients have lower immunological and virological responses at 48 weeks from ART initiation than monoinfected patients.

Abbreviations: χ² = chi-squared test, μL = microliter, AIDS = acquired immunodeficiency syndrome, ART = antiretroviral therapy, CI = confidence interval, CIBERESP = Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, CoRIS = Cohort of Spanish HIV Research Network, DAA’s = direct-acting antivirals, HBsAg = hepatitis B surface antigen, HCV = Hepatitis C Virus, HIV = Human Immunodeficiency Virus, IDU = Injecting Drugs Users, IQR = Interquartile Range, mL = milliliter, MSM = men who have sex with men, OR = odds ratio, RNA = ribonucleic acid, STR = single-tablet regimens.

Keywords: antiretroviral therapy, cohort study, Hepatitis C virus, HIV/AIDS, HIV/HCV co-infection, response to treatment
1. Introduction

Coinfection with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) has been associated with a faster progression of hepatitis and higher liver-related mortality.\[1-3\] However, the effect of co-infection on HIV progression and responses to HIV antiretroviral therapy (ART) seems less clear. Various studies have reported poorer immunological response to ART in HIV/HCV co-infected patients,\[4-11\] whereas others have not found significant differences.\[12-15\] Regarding the virological response to ART, most studies have not found significant differences,\[7,8,12,16\] although Hua et al\[9\] reported a worse response in co-infected patients. It could be argued that inconsistent results might be explained by the heterogeneity of the populations in the different studies, the different study periods reflecting diverse ART regimens and small sample sizes.\[9,16\]

However, there are well-described biological mechanisms that could explain the different responses observed between co-infected and monoinfected individuals.\[1,17-19\]

The estimated global prevalence of HCV coinfection in HIV-positive individuals in 2013 was between 9.2% and 37.3%,\[20\] and Spain was situated on the top of the rank in 2015.\[21\] This very high prevalence of HCV coinfection in HIV-positive persons in Spain reflects a unique HIV epidemiological pattern pertaining the elevated numbers of persons who became infected through illicit drug use in the 1980s and 1990s which has declined over time, and with it, the proportion of co-infected subjects.\[12\]

Given the inconsistencies previously highlighted in the literature, the major changes in HIV clinical management in recent years and the lack of contemporary data addressing this question in Spain, we aimed to assess the effect of coinfection by HCV on immunological and virological response at 48 weeks from ART initiation in HIV-positive patients in the Cohort of the Spanish HIV Research Network (CoRIS) from January 2004 till November 2015. Additionally, we also modeled immunological responses in patients with optimal HIV responses to ART.

2. Methods

2.1. Study design, setting and participants

The Cohort of the Spanish HIV Research Network (CoRIS) is an open, multicenter, prospective cohort of HIV-infected individuals older than 13 years, naïve to ART at study entry, seen for the first time from 1 January 2004 at any of the 42 centers in 13 of the 17 autonomous regions in Spain. Subjects agree to participate in the study by signing an informed consent form. Ethics approval was obtained from all hospitals Ethics Committees and every patient provides written informed consent to participate. CoRIS collects a minimum data set as described in the cohort protocol, which includes baseline and follow-up sociodemographic, immunological, and clinical data. Data are subjected to internal quality controls. Patients are followed periodically under routine clinical practice.\[23\]

Patients considered for inclusion were baseline ART naïve patients, aged ≥18 years, who started ART between 1 January 2004 and 30 November 2014 and had a CD4 T-cell count and an HIV viral load measurement both in the previous 6 months and at 48 (±12) weeks from ART initiation, and HCV serology previous to ART initiation. Because direct-acting antivirals (DAAs) were not widely available in Spain at the time of these analyses, none of the patients included had received them. Information regarding HCV treatment with interferon and ribavirin was not collected at the time and was, therefore, not taken into account in the analysis. A detailed flow chart is shown in Figure 1.

![Figure 1. Flowchart of the study population.](image-url)
2.2. Variables and definitions

CoRIS collects information about birthdate, sex (male, female), geographical origin, education level (high school or lower, secondary, university, unknown), age, and year at start of ART, HIV-transmission category (men who have sex with men [MSM], injecting drugs users [IDU], heterosexual, unknown), CD4 T-cell count, HIV viral load, acquired immunodeficiency syndrome (AIDS) progression, hepatitis B surface antigen, hepatitis C antibodies, follow-up center, initial ART regimen, among others.

Subjects were classified at baseline as HIV-monoinfected and HIV/HCV-coinfected based on HCV serological findings.

2.3. Outcomes

Immunological response was defined as the change in CD4 T-cell counts at week 48 (±12) from ART initiation, and virological response as achieving a viral load <50 HIV-1 ribonucleic acid (RNA) copies/milliliter (mL) at 48 (±12) weeks from ART initiation.

2.4. Statistical analysis

A descriptive analysis of patients’ characteristics was carried out using frequency tables for categorical variables and median and interquartile range (IQR) for continuous variables. Differences in sociodemographic and clinical characteristics between HIV/HCV-coinfected and HIV-monoinfected patients were assessed through the nonparametric Mann–Whitney test for continuous variables and the χ² test for independence for categorical variables.

Linear regression models were used to estimate the mean difference in the increase in CD4 T-cell counts at week 48 (±12) from ART initiation, comparing HIV/HCV-coinfected versus HIV-monoinfected patients. Logistic regression models were used to estimate the odds ratio (OR) for the association between HIV/HCV coinfection and virological response at week 48 (±12) from the start of ART.

All the models were adjusted for potential confounders defined a priori: sex, age at start ART, HIV transmission category, geographical origin, educational status, CD4 T cells count pre-ART, HIV viral load pre-ART and AIDS pre-ART, hepatitis B infection pre-ART, and year at start ART. We assessed whether any of the variables studied modified the effect of HCV co-infection on immunological and virological response by including interaction terms in multivariable models.

We considered a possible interaction for period effect, in relation with 2 major changes on ART in 2008: extended use of single-tablet regimens (STR) that improves adherence and viral suppression [24] and widespread introduction of integrase inhibitors. [25] Because of that, we performed a sensitivity analysis, looking for the outcomes variables in both periods 2004 to 2007 and 2008 to 2013.

We considered the possibility of poor adherence in relation to no viral suppression, proposed in other studies, and modeled immunological responses in patients with optimal virological responses.

To adjust for clustering of patients within centers, robust methods were used to estimate standard errors and, thus, to calculate 95% confidence intervals (CI) and P values. Wald tests were used to derive P values. All statistical analyses were performed using Stata software (version 14.0; Stata Corporation, College Station, TX).

3. Results

3.1. Study population

CoRIS database, updated at 30 November 2015, included 12,239 individuals of whom 5070 met the inclusion criteria (Fig. 1), 4382 (86.4%) were HIV-monoinfected and 688 (13.6%) were HIV/HCV-coinfected patients. HIV/HCV-coinfected patients were more likely than those HIV-monoinfected to have acquired HIV through injecting drugs use, to be women, older at the start of ART, of Spanish origin with lower education level, and started ART with a lower CD4 count and an AIDS diagnosis (Table 1).

3.2. Change in CD4 T-cell counts at week 48 from ART initiation

Mean (95% CI) CD4 T-cell increase at week 48 from ART initiation was 229.7 (224.2–235.2) cells/µL in HIV-monoinfected patients.

### Table 1

| Sociodemographic and clinical characteristics. | HIV mono-infected | HIV/HCV co-infected | P |
|-----------------------------------------------|------------------|---------------------|---|
| N                                             | 4382 (86.4)      | 688 (13.6)          | <.001 |
| Sex, N (%)                                     |                   |                     |     |
| Male                                          | 3662 (83.6)      | 517 (75.2)          |     |
| Female                                        | 720 (16.4)       | 171 (24.9)          |     |
| Age at start of ART, y, N (%)                 |                   |                     |     |
| Median (IQR)                                   | 36.4 (30.5–43.7) | 41.8 (36.7–46.4)    | <.001 |
| <50                                           | 3821 (87.2)      | 597 (88.6)          | .76  |
| ≥50                                           | 561 (12.8)       | 91 (13.2)           |     |
| HIV transmission category, N (%)              |                   |                     |     |
| MSM                                           | 2743 (62.6)      | 95 (13.8)           |     |
| IDU                                           | 46 (1.1)         | 396 (57.4)          |     |
| Heterosexual                                  | 1454 (33.2)      | 177 (25.7)          |     |
| Unknown                                       | 139 (3.2)        | 21 (3.1)            |     |
| Education level, N (%)                        |                   |                     | <.001 |
| High school or lower                          | 1405 (32.1)      | 392 (57.0)          |     |
| Secondary                                     | 1238 (28.3)      | 142 (20.7)          |     |
| University                                    | 1100 (25.1)      | 42 (6.1)            |     |
| Unknown                                       | 639 (14.6)       | 112 (16.3)          |     |
| Origin, N (%)                                 |                   |                     | <.001 |
| Spain                                         | 2974 (67.9)      | 582 (84.6)          |     |
| Not Spain                                     | 1408 (32.1)      | 106 (15.4)          |     |
| CD4 count pre-ART, cells/µL, N (%)            |                   |                     |     |
| Median (IQR)                                   | 288 (166–401)    | 220 (96–342)        | <.001 |
| <200                                          | 1377 (31.4)      | 299 (43.5)          | <.001 |
| 200–350                                       | 1502 (34.3)      | 233 (32.4)          |     |
| ≥350                                          | 1503 (34.3)      | 166 (24.1)          |     |
| HIV VL pre-ART, copies/mL, N (%)              |                   |                     | <.001 |
| Median (IQR)                                   | 70,490 (21,123)  | 68,695 (15,924)     | .22  |
| <100000                                       | 671 (15.3)       | 132 (19.2)          | .03  |
| >100000                                       | 1947 (44.4)      | 286 (41.6)          |     |
| AIDS pre-ART, N (%)                           |                   |                     | <.001 |
| Positive                                      | 3784 (84.4)      | 529 (76.9)          |     |
| Negative                                      | 598 (13.7)       | 159 (23.1)          | .42  |
| HBSAg pre-ART, N (%)                          |                   |                     |     |
| Positive                                      | 3795 (86.6)      | 585 (85.0)          |     |
| Negative                                      | 169 (3.9)        | 33 (4.8)            |     |
| Unknown                                       | 418 (9.5)        | 70 (10.2)           |     |
| Initial ART regimen, N (%)                    |                   |                     |     |
| 2 NRTI + 1 NRTI                               | 2553 (58.3)      | 310 (45.1)          | <.001 |
| 2 NRTI + 1 PI                                 | 809 (18.5)       | 158 (23.0)          |     |
| NRTI + 1 PI                                   | 879 (20.1)       | 194 (28.2)          |     |
| Other                                         | 89 (2.0)         | 21 (3.1)            |     |
| Nonspecified                                  | 52 (1.2)         | 5 (0.7)             |     |
| Year at start of ART, N (%)                   |                   |                     | <.001 |
| Median (IQR)                                   | 2010 (2006–2012) | 2008 (2006–2011)    |     |
| 2004–2007                                     | 1943 (23.8)      | 278 (40.4)          |     |
| 2008–2014                                     | 3339 (76.2)      | 410 (59.6)          |     |

ART = antiretroviral therapy, AIDS = acquired immunodeficiency syndrome, HBSAg = hepatitis B surface antigen, HCV = hepatitis C virus, HIV = human immunodeficiency virus, HIV-VL = HIV viral load, IDU = injection drug use, IQR = interquartile range, mL = milliliter, MSM = men who have sex with men, N = number, NRTI = non-nucleoside reverse transcriptase inhibitor, NRTI = nucleoside reverse transcriptase inhibitor, PI = protease inhibitor, µL = microliter.
Impact of coinfection by HCV on immunological Response at 48 weeks from ART initiation.

|                  | Univariable analyses | Multivariable analyses |
|------------------|----------------------|------------------------|
|                  | n                    | Mean of increase in CD4 T-cell count, cells/µL, 95% CI | Difference in mean CD4 T-cell count increase, cells/µL, 95% CI | P         | Difference in mean CD4 T-cell count increase, cells/µL, 95% CI | P         |
| HCV (-)          | 4382                 | 229.7 (224.2–235.2)   | 0                      | .001      | 0                      | .001      |
| HCV (+)          | 688                  | 161.9 (149.7–174.2)   | −67.8 (−87.4 to −48.1) | <.001     | −44.5 (−64.3 to −24.8) | <.001     |

*Adjusted for HIV transmission category.

ART = antiretroviral therapy, CI = confidence interval, HCV = hepatitis C virus, µL = microliter.

patients versus 161.9 (149.7–174.2) cells/µL in HIV/HCV-coinfected patients (P < .001). In univariable analyses, the difference in mean CD4 T-cell count increase between HIV/ HCV-coinfected and HIV-monoinfected patients was 67.8 (95% CI: 48.1–87.4) cells/µL. After adjustment for HIV transmission category, which appeared to be the only variable that confounded the association of interest, the difference in mean CD4 T-cell count increase was reduced to 44.5 cell/µL (95% CI: 24.8–64.3) but remained statistically significant (P < .001) (Table 2). We failed to find any evidence suggesting that any of the variables studied modified the effect of HCV-coinfection on the immunological response to ART, including a possible period effect (all interaction P values ≥.05).

We modeled immunological responses in patients with optimal virological responses, and we found that the difference in mean CD4 T-cell count increase was reduced to 37.1 cell/µL (95% CI: 15.1–59.2) but remained statistically significant (P = .002).

### 3.3. Virological response at 48 weeks after ART initiation

At 48 weeks from ART initiation, 87.0% of HIV-monoinfected patients and 78.3% of HIV/HCV-coinfected patients achieved virological response (P < .001). As for immunological response, HIV transmission category was the only variable that confounded the association of interest and after adjustment for this characteristic in a multivariable logistic regression model, HIV/ HCV-coinfected patients still had a lower chance of achieving virological response than HIV-coinfected patients (adjusted OR 0.62; 95% CI: 0.44–0.88; P < .01) (Table 3).

There was no evidence suggesting that any of the variables studied modified the effect of HCV-coinfection on immunological response, including a possible period effect (all interaction P values ≥.05).

### 4. Discussion

We found that HIV/HCV-coinfected patients within a national and representative cohort in Spain had poorer immunological and virological responses at 48 weeks from ART initiation than monoinfected patients. We observed these findings in crude and adjusted analyses, and saw no differential effect of HCV coinfection on HIV immunological and virological responses to ART from 2004 until 2015, before the widespread introduction of DAA's for the treatment of HCV infection in Spain.[26] Consequently, we could not see its effects in this analysis.

Our results are consistent with the poorer immunological response at 48 weeks from ART initiation in HIV/HCV-coinfected compared to monoinfected patients reported in many studies,[7,8,10,12,16,27] although not in others.[12] Of note, our results provide contemporary data supporting the inferior virological response in coinfected patients compared to monoinfected patients described by Hua et al[10] 15 years ago. It must be mentioned, however, that most studies have not found statistically significant differences in virological responses to ART by HCV infection status.

Many possible reasons explaining the worse responses to ART of HIV/HCV-coinfected individuals have been proposed. Social factors, which differentially affect people dually infected with HIV and HCV, have been suggested as potential confounders or mediators. Additionally, biological factors connected to HCV pathogenicity are to be taken into account.

The social and behavioral factors associated with HCV infection, which could contribute to explain the worse responses to ART observed in our study include various forms of drug dependency,[16,27] higher-risk sexual behavior,[3] barriers to accessing health care,[28] and poorer linkage and retention in care.[29-33] In the present study, we have adjusted by HIV transmission category, the main behavioral factor, which accounted for the differences between groups, other social factors such as geographical origin and education level. Indeed, as far as we are aware, no previous study addressing this question has adjusted for this proxy of socioeconomic level. All other possible confounders have been evaluated like AIDS state, Hepatitis B co-infection, and the possibility of a period effect in relation to changes in ART (widespread introduction of STR and integrase inhibitors). Additionally, initial treatment regimen has been assessed, as it can affect the response (schedules that includes integrase inhibitors can achieve virological response...
faster than others), without finding significant differences between groups. Also, sensitivity analyses have been carried out, comparing immunological response between groups, only in the individuals with optimal virological responses, and the differences between groups remained. Also, Cescon et al.\(^{14}\) compared the immunological and virological responses between HIV/HCV-coinfected IDU and HIV/HCV-coinfected non-IDU individuals, finding no differences in virological response and just a marginal difference in immunological response. This can support a direct biological effect of HCV on the responses.

Among the biological factors explaining the effect of HCV on ART responses, it has been found that in HIV/HCV co-infected patients, immune activation of memory CD4 T-cells is considerably increased,\(^{19}\) so is longer immune activation associated with high CD38 expression in T-cells, regardless of receiving ART.\(^{18}\) It has been described that HCV viral proteins can act as ligands for cell receptors of the immune system, among other cells, like HCV E2 protein can bind to the CD81 receptor and infect T-cells, B-cells, and monocytes.\(^{1,27}\) HCV core significantly seems to enhance HIV replication in human macrophages by upregulating Tumoral Necrosis Factor and interleukin-6.\(^{17}\) These mechanisms could explain the different evolution of the HIV infection in HIV/HCV-coinfected individuals.

As a limitation of the present study, information on HCV viral loads was not available for most patients, so we used HCV serology before ART initiation to classify them as mono or coinfected. In consequence, patients who spontaneously cleared HCV infection could have been wrongly classified as HIV/HCV coinfected patients. However, we do not think this might have biased our study as spontaneous clearance is believed to be even lower among HIV/HCV co-infected individuals,\(^{18}\) and in any case, this misclassification bias goes toward the null hypothesis.

As strengths, this cohort includes patients from all over Spain with a broad spectrum of patient characteristics and antiretroviral regimens and is representative of the contemporary HIV epidemic. The overall number of patients was very high, limiting misclassification errors related to the collection of information. ART in the patients from the cohort is adjusted to national HIV treatment guidelines.\(^{23}\)

The findings of this study have implications for clinical practice and public health. It is evident that HCV itself has a negative effect on the response to ART in HIV/HCV co-infected patients. Knowing that HCV infection has an effective treatment, boosting access to this treatment has an impact on HCV infection, but also has an impact on HIV infection and epidemic. As future work, repeating these analyses in the same cohort when HIV/HCV-coinfected patients have been treated for HCV may serve to strengthen the evidence of the need for HCV treatment, mainly as a public health approach in low-income countries where these 2 infections have a significant effect and/or where effective HCV treatment is not available.

**Acknowledgments**

Centers and investigators involved in the Cohort of the Spanish HIV Research Network (CoRIS): Executive committee: Santiago Moreno, Julia del Amo, David Dalmàu, Laura Luisa Navarro, Maria Isabel González, Jose Luis Blanco, Federico García, Rafael Rubio, Jose Antonio Iribarren, Félix Gutíérrez, Francesc Vidal, Juan Berenguer, Juan González.

Fieldwork, data management and analysis: Paz Sobrino, Victoria Hernando, Belén Alejos, Débora Álvarez, Inma Jarrín, Nieves Sanz, Cristina Moreno.

BioBanK HIV: M Ángeles Muñoz-Fernández, Isabel García-Merino, Coral Gómez Rico, Jorge Gallego de la Fuente and Almudena García Torre.

Participating centres: Hospital General Universitario de Alicante (Alicante): Joaquín Portilla, Esperanza Merino, Sergio Reus, Vicente Boix, Livia Giner, Carmen Gadea, Irene Portilla, Maria Pampliega, Marcos Diez, Juan Carlos Rodríguez, Jose Sánchez-Payá.

Hospital Universitario de Canarias (San Cristobal de la Laguna): Juan Luis Gómez, Jehovana Hernández, María Remedios Alemán, María del Mar Alonso, María Inmaculada Hernández, Felicitas Díaz-Flores, Dácil García, Ricardo Pelazas, Ana López Lirola.

Hospital Universitario Central de Asturias (Oviedo): Victor Asensi, Eulalia Valle, José Antonio Carton, María Eugenia Rivas Carmenado.

Hospital Universitario 12 de Octubre (Madrid): Rafael Rubio, Federico Pulido, Otilia Bisbal, Asunción Hernando, María Lagarde, Mariano Matarraz, Lourdes Domínguez, Laura Bermejo, Mireia Santacreu.

Hospital Universitario Donostia (Donostia-San Sebastián): José Antonio Iribarren, Julio Arizabalaga, María José Aramburu, Xabier Camino, Francisco Rodríguez-Arrondo, Miguel Ángel von Wichmann, Lidia Pascual Tomé, Miguel Ángel Goenaq, M Jesús Bustinduy, Harkaitz Azañke Galparso, Maiailen Ibariguren, Maitane Umezer.

Hospital General Universitario De Elche (Elche): Félix Gutiérrez, Mar Másiá, Sergio Padilla, Andrés Navarro, Fernando Montolio, Catalina Robledano, Joan Gregori Colomé, Araceli Aduas, Rafael Pascual, Marta Fernández, Elena García-José Alberto García, Xavier Barber.

Hospital Universitari Germans Trias i Pujol (Can Ruti) (Badalona): Roberto Muga, Jordi Tor, Aranza Sanvisens.

Hospital General Universitario Gregorio Marañón (Madrid): Juan Berenguer, Juan Carlos López Bernalado de Quirós, Pilar Miralles, Isabel Gutiérrez, Margarita Ramírez, Belén Padilla, Paloma Gijón, Ana Carrero, Teresa Aklamis-Echevarría, Francisco Téterina, Francisco Jose Parras, Pascual Balsalobre, Cristina Diez.

Hospital Universitari de Tarragona Joan XXIII (Tarragona): Francesc Vidal, Joaquín Peraire, Consuelo Viladés, Sergio Veloso, Montserrat Vargas, Miguel López-Dupla, Montserrat Olona, Anna Rull, Esther Rodriguez-Gallego, Verónica Alba.

Hospital Universitario y Politécnico de La Fe (Valencia): Manta Montero Alonso, José López Aldegue, Marino Blanes Juliá, Mariona Tasis Pitarach, Iván Castro Hernández, Eva Calabuig Muñoz, Sandra Cuellar Tovar, Miguel Salavert Lleti, Juan Fernando Navarro.

Hospital Universitario La Paz-CarlosIII-Cantoblanco: Juan González-García, F Arnalich, José Ramón Arribas, José Ignacio Bernardino, Juan Miguel Castro, Luis Escosa, Pedro Herranz, Victor Hontaño, Silvia García-Bujalance, Milagros García López-Hortelano, Alicia Gonzalez-Baeza, María Luz Martín-Carbonero, Mario Mayoral, María José Mellado, Rafael Micán, Rocio Montejo, María Luisa Montes, Victoria Moreno, Ignacio Pérez-Valero, Berta Rodés, Talla Sainz, Elena Sendagorta, Natalia C Stella y Eulalia Valencia.

Hospital San Pedro Centro de Investigación Biomédica de La Rioja (CIBIR) (Logroño): José Ramón Blanco, José Antonio Oteo, Valvanera Ibarra, Luis Metola, Mercedes Sanz, Laura Pérez-Martínez.
References

[1] Liberto MC, Zacca E, Pavia G, et al. Virological mechanisms in the co-infection between HIV and HCV. Mediators Inflamm 2015;2015:320352.

[2] Hernandez MD, Sherman KE. HIV/HCV coinfection natural history and disease progression, a review of the most recent literature. Curr Opin HIV AIDS 2011;6:478–82.

[3] Arends JE, Lieveld FI, Boeijen LL, et al. Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms? J Hepatol 2011;6:478.

[4] Motta D, Brianese N, Focà E, et al. Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received. AIDS Res Ther 2012;9:18.

[5] Law WP, Duncombe CJ, Mahonemharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS Lond Engl 2004;18:1169–77.
[6] Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003;163:2187–95.

[7] De Luca A, Bugarrini R, Lepré AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002;162:215–22.

[8] Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003;4:241–9.

[9] Hua L, Andersen JW, Daar ES, et al. Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment. AIDS Lond Engl 2013;27:2725–34.

[10] Marcus JL, Leyden WA, Chao CR, et al. Differences in response to antiretroviral therapy by sex and hepatitis C infection status. AIDS Patient Care STDs 2015;29:370–8.

[11] Macías J, Pineda JA, Lozano F, et al. Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naive patients coinfected with human immunodeficiency virus and hepatitis C virus. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 2003;22:675–80.

[12] Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005;192:992–1002.

[13] Collazos J, Martín JA, Asensi V. Evaluation of the possible influence of hepatitis C virus and liver fibrosis on HIV type 1 immunological and virological outcomes. HIV Med 2011;12:308–13.

[14] Sulkowski MS. Management of acute and chronic HCV infection in persons with HIV coinfection. J Hepatol 2014;61(suppl):S108–19.

[15] Weimer LE, Fragola V, Florida M, et al. Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. J Antimicrob Chemother 2013;68:193–9.

[16] Weiss N, Lindhardt BO, Kronborg G, et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis Off Publ Infect Dis Soc Am 2006;42:1481–7.

[17] Swaminathan G, Pascual D, Rival G, et al. Hepatitis C virus core protein enhances HIV-1 replication in human macrophages through TLR2, JNK, and MEK1/2-dependent upregulation of TNF-α and IL-6. FEBS Lett 2014;588:3501–10.

[18] Gonzalez VD, Falconer K, Blom KG, et al. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009;83:11407–11.

[19] Al-Harthi L, Voris J, Du W, et al. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis 2006;193:1202–10.

[20] Basnayake SK, Easterbrook PJ. Wide variation in estimates of global prevalence and burden and death estimates from chronic HBV, HCV and coinfection with HIV in literature. J Viral Hepat 2016;23:545–59.

[21] Berenguer J, Rivero A, Jarrín I, et al. HIV/HCV coinfection in Spain: prevalence and patient characteristics. J Hepatol 2016;64:S617.

[22] Perea-Cachafeiro S, Del Amo J, Iribarren JA, et al. Decrease in seroconversion with hepatitis C virus among HIV-infected patients in Spain, 1997–2006. Clin Infect Dis Off Publ Infect Dis Soc Am 2009;48:1467–70.

[23] Suarez-Garcia I, Sobrino-Vegas P, Tejada A, et al. Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: a study in a Spanish cohort. HIV Med 2014;15:86–97.

[24] Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis Off Publ Infect Dis Soc Am 2014;58:1297–307.

[25] Meint Mixer, Marchand C, Poix M. De Clercq E. Integrate inhibitors: 20-year landmark and challenges. Advances in Pharmacology 2013; Academic Press, 75–105. Available at: http://www.sciencedirect.com/science/article/pii/B9780124058804000032.

[26] Asociación Española para el Estudio del Hígado (AEEH), Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Guías AEEH/SEIMC de manejo de la Hepatitis C. 2016. Available at: https://www.seimc.org/contenidos/documentoscientificos/guiasclinicas/seimc-clinicasclinicas-2016-Manejo_HepatitisC.pdf.

[27] Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet Lond Engl 2000;356:1800–5.

[28] Fleming CA, Craven DE, Thornton D, et al. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis Off Publ Infect Dis Soc Am 2003;36:97–100.

[29] Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS Lond Engl 2011;15:1707–15.

[30] van Asten LC, Rouffaas F, Schiffer V, et al. Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level. Eur J Public Health 2003;13:347–9.

[31] Wood E, Montaner JG, Yip B, et al. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antivir Ther 2004;9:229–35.

[32] Dronda F, Zamora J, Moreno S, et al. CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use. AIDS Lond Engl 2004;18:2120–2.

[33] Micaleff JM, Macdonald V, Jannex M, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 2007;14:413–8.

[34] Cesco A, Chan K, Raboud JM, et al. Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history. AIDS Lond Engl 2014;28:121–7.

[35] Thomas DL, Atemborski J, Ral RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450–6.